@article{f870e0a820f9439492085cb61d1aab20,
title = "A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study",
author = "D.P. Bender and M. Sill and H. Lankes and C.J. Darus and J. Delmore and J. Rotmensch and H.J. Gray and R.S. Mannel and J.M. Schilder and K.K. Leslie and H.D. Reyes and M. Hunter and C.K. McCourt and M. Samuelson",
note = "Objectives: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess the activity and tolerability of single-agent cediranib in recurrent or persistent endometrial cancer.",
year = "2015",
month = may,
day = "1",
doi = "10.1016/J.YGYNO.2015.04.018",
language = "American English",
volume = "138",
journal = "Gynecologic Oncology",
issn = "1095-6859",
publisher = "Elsevier",
}